Gallstones are a known risk with GLP-1 medications, mostly tied to rapid weight loss rather than the medication itself.
Clinical trials of Semaglutide and Tirzepatide show gallbladder-related events (gallstones, gallbladder inflammation, gallbladder removal) at rates of around 2 to 4% of users, slightly higher than placebo. The mechanism appears to be:
Symptoms to watch for:
If you experience these, seek medical attention promptly — gallstones blocking the bile duct can become a medical emergency.
Things that may reduce risk:
If you have a history of gallstones or gallbladder issues, talk to your provider before starting a GLP-1 — they may want to monitor more closely or adjust your titration. Most people will not develop gallstones, and the cardiovascular and metabolic benefits of these medications often outweigh the risk for those who qualify.
Different ways people phrase this question. Each expands to the same answer.
Gallstones are a known risk with GLP-1 medications, mostly tied to rapid weight loss rather than the medication itself.
Clinical trials of Semaglutide and Tirzepatide show gallbladder-related events (gallstones, gallbladder inflammation, gallbladder removal) at rates of around 2 to 4% of users, slightly higher than placebo. The mechanism appears to be:
Symptoms to watch for:
If you experience these, seek medical attention promptly — gallstones blocking the bile duct can become a medical emergency.
Things that may reduce risk:
If you have a history of gallstones or gallbladder issues, talk to your provider before starting a GLP-1 — they may want to monitor more closely or adjust your titration. Most people will not develop gallstones, and the cardiovascular and metabolic benefits of these medications often outweigh the risk for those who qualify.
Gallstones are a known risk with GLP-1 medications, mostly tied to rapid weight loss rather than the medication itself.
Clinical trials of Semaglutide and Tirzepatide show gallbladder-related events (gallstones, gallbladder inflammation, gallbladder removal) at rates of around 2 to 4% of users, slightly higher than placebo. The mechanism appears to be:
Symptoms to watch for:
If you experience these, seek medical attention promptly — gallstones blocking the bile duct can become a medical emergency.
Things that may reduce risk:
If you have a history of gallstones or gallbladder issues, talk to your provider before starting a GLP-1 — they may want to monitor more closely or adjust your titration. Most people will not develop gallstones, and the cardiovascular and metabolic benefits of these medications often outweigh the risk for those who qualify.
Gallstones are a known risk with GLP-1 medications, mostly tied to rapid weight loss rather than the medication itself.
Clinical trials of Semaglutide and Tirzepatide show gallbladder-related events (gallstones, gallbladder inflammation, gallbladder removal) at rates of around 2 to 4% of users, slightly higher than placebo. The mechanism appears to be:
Symptoms to watch for:
If you experience these, seek medical attention promptly — gallstones blocking the bile duct can become a medical emergency.
Things that may reduce risk:
If you have a history of gallstones or gallbladder issues, talk to your provider before starting a GLP-1 — they may want to monitor more closely or adjust your titration. Most people will not develop gallstones, and the cardiovascular and metabolic benefits of these medications often outweigh the risk for those who qualify.